XCNQ
BIOV
Market cap7mUSD
Jun 24, Last price
0.04CAD
1D
-12.50%
1Q
-30.00%
IPO
-33.33%
Name
Biovaxys Technology Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-8m
L-60.29%
CFO
-2m
L+76.54%
Profile
BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. The company is based in Vancouver, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑10 | 2023‑10 | 2022‑10 | 2021‑10 | 2020‑10 | 2019‑10 | 2018‑10 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | 2,403 | 4,082 | |||||
Unusual Expense (Income) | |||||||
NOPBT | (2,403) | (4,082) | |||||
NOPBT Margin | |||||||
Operating Taxes | 7,630 | ||||||
Tax Rate | |||||||
NOPAT | (2,403) | (11,712) | |||||
Net income | (7,687) -60.29% | (19,357) 199.01% | |||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 3,161 | 917 | 1,108 | ||||
BB yield | -5.51% | ||||||
| Debt | |||||||
Debt current | 68 | ||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | 1,313 | ||||||
Net debt | (144) | (977) | (293) | ||||
| Cash flow | |||||||
Cash from operating activities | (1,862) | (1,055) | (1,575) | ||||
CAPEX | (1,056) | ||||||
Cash from investing activities | (1,056) | ||||||
Cash from financing activities | 3,127 | 917 | 1,108 | ||||
FCF | (1,608) | 132 | (10,787) | ||||
| Balance | |||||||
Cash | 212 | 977 | 142 | ||||
Long term investments | 151 | ||||||
Excess cash | 212 | 977 | 293 | ||||
Stockholders' equity | (1,943) | (3,372) | (774) | ||||
Invested Capital | 91 | ||||||
ROIC | |||||||
ROCE | 71.25% | 527.68% | |||||
| EV | |||||||
Common stock shares outstanding | 134,143 | 98,180 | |||||
Price | 0.07 | 0.21 -44.59% | |||||
Market cap | 20,127 -34.41% | ||||||
EV | 19,834 | ||||||
EBITDA | (2,403) | (4,082) | |||||
EV/EBITDA | |||||||
Interest | 16 | ||||||
Interest/NOPBT | |||||||